| . | Overall-44, N (%) . | Simultaneous group . | Staged group . | ||||
|---|---|---|---|---|---|---|---|
| . | . | Overall-25, N (%) . | EVAR first-18, N (%) . | TAVI first-7, N (%) . | Overall-19, N (%) . | EVAR first-10, N (%) . | TAVI first–9, N (%) . |
| Preoperative factors | |||||||
| Male | 30 (68) | 13 (52) | 7 (39) | 5 (71) | 17 (89) | 9 (90) | 8 (89) |
| Urgent aneurysm | 3 (7) | 0 (0) | 0 (0) | 0 (0) | 3 (16) | 3 (30) | 0 (0) |
| Hostile bilateral femoral/iliac access | 11 (25) | 5 (20) | 4 (22) | 1 (14) | 6 (32) | 3 (30) | 3 (33) |
| TEVAR | 8 (57) | 3 (12) | 3 (17) | 0 (0) | 5 (26) | 2 (20) | 3 (33) |
| EVAR | 36 (43) | 22 (88) | 15 (83) | 7 (100) | 14 (74) | 8 (80) | 6 (67) |
| Days between procedures (Staged group) | 72 (IQR: 57–87) | 82 (IQR: 32–86) | 65 (IQR: 28–88) | ||||
| Intraoperative details | |||||||
| General Anaesthesia TEVAR/EVAR | 23 (52) | 14 (56) | 13 (72) | 1 (14) | 9 (47) | 3 (30) | 6 (67) |
| Percutaneous femoral access TEVAR/EVAR | 27 (61) | 16 (64) | 10 (56) | 6 (86) | 11 (58) | 4 (40) | 7 (78) |
| Percutaneous femoral access TAVI | 30 (68) | 16 (64) | 10 (56) | 6 (86) | 14 (74) | 7 (70) | 7 (78) |
| Need for iliac adjunctive procedures | 4 (9) | 1 (4) | 0 (0) | 1 (14) | 3 (16) | 2 (20) | 1 (11) |
| Technical Success | 44 (100) | 25 (100) | 18 (100) | 7 (100) | 19 (100) | 10 (100) | 9 (100) |
| Postoperative results | |||||||
| Cardiac adverse events | 2 (5) | 0 (0) | 0 (0) | 0 (0) | 2 (11) | 1 (10) | 1 (11) |
| Cerebrovascular adverse events | 2 (5) | 1 (4) | 0 (0) | 1 (14) | 1 (5) | 0 (0) | 1 (11) |
| Respiratory adverse events | 5 (11) | 0 (0) | 0 (0) | 0 (0) | 5 (26) | 2 (20) | 3 (33) |
| Reinterventions | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 1 (5) | 1 (10) | 0 (0) |
| Vascular access complication | 2 (5) | 1 (4) | 1 (6) | 0 (0) | 1 (5) | 0 (0) | 1 (11) |
| Death | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 1 (5) | 1 (10) | 0 (0) |
| . | Overall-44, N (%) . | Simultaneous group . | Staged group . | ||||
|---|---|---|---|---|---|---|---|
| . | . | Overall-25, N (%) . | EVAR first-18, N (%) . | TAVI first-7, N (%) . | Overall-19, N (%) . | EVAR first-10, N (%) . | TAVI first–9, N (%) . |
| Preoperative factors | |||||||
| Male | 30 (68) | 13 (52) | 7 (39) | 5 (71) | 17 (89) | 9 (90) | 8 (89) |
| Urgent aneurysm | 3 (7) | 0 (0) | 0 (0) | 0 (0) | 3 (16) | 3 (30) | 0 (0) |
| Hostile bilateral femoral/iliac access | 11 (25) | 5 (20) | 4 (22) | 1 (14) | 6 (32) | 3 (30) | 3 (33) |
| TEVAR | 8 (57) | 3 (12) | 3 (17) | 0 (0) | 5 (26) | 2 (20) | 3 (33) |
| EVAR | 36 (43) | 22 (88) | 15 (83) | 7 (100) | 14 (74) | 8 (80) | 6 (67) |
| Days between procedures (Staged group) | 72 (IQR: 57–87) | 82 (IQR: 32–86) | 65 (IQR: 28–88) | ||||
| Intraoperative details | |||||||
| General Anaesthesia TEVAR/EVAR | 23 (52) | 14 (56) | 13 (72) | 1 (14) | 9 (47) | 3 (30) | 6 (67) |
| Percutaneous femoral access TEVAR/EVAR | 27 (61) | 16 (64) | 10 (56) | 6 (86) | 11 (58) | 4 (40) | 7 (78) |
| Percutaneous femoral access TAVI | 30 (68) | 16 (64) | 10 (56) | 6 (86) | 14 (74) | 7 (70) | 7 (78) |
| Need for iliac adjunctive procedures | 4 (9) | 1 (4) | 0 (0) | 1 (14) | 3 (16) | 2 (20) | 1 (11) |
| Technical Success | 44 (100) | 25 (100) | 18 (100) | 7 (100) | 19 (100) | 10 (100) | 9 (100) |
| Postoperative results | |||||||
| Cardiac adverse events | 2 (5) | 0 (0) | 0 (0) | 0 (0) | 2 (11) | 1 (10) | 1 (11) |
| Cerebrovascular adverse events | 2 (5) | 1 (4) | 0 (0) | 1 (14) | 1 (5) | 0 (0) | 1 (11) |
| Respiratory adverse events | 5 (11) | 0 (0) | 0 (0) | 0 (0) | 5 (26) | 2 (20) | 3 (33) |
| Reinterventions | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 1 (5) | 1 (10) | 0 (0) |
| Vascular access complication | 2 (5) | 1 (4) | 1 (6) | 0 (0) | 1 (5) | 0 (0) | 1 (11) |
| Death | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 1 (5) | 1 (10) | 0 (0) |
EVAR: endovascular aortic repair; IQR: interquartile range; N: numbers; TAVI: transcatheter aortic valve implantation; TEVAR: thoracic endovascular aortic repair.
| . | Overall-44, N (%) . | Simultaneous group . | Staged group . | ||||
|---|---|---|---|---|---|---|---|
| . | . | Overall-25, N (%) . | EVAR first-18, N (%) . | TAVI first-7, N (%) . | Overall-19, N (%) . | EVAR first-10, N (%) . | TAVI first–9, N (%) . |
| Preoperative factors | |||||||
| Male | 30 (68) | 13 (52) | 7 (39) | 5 (71) | 17 (89) | 9 (90) | 8 (89) |
| Urgent aneurysm | 3 (7) | 0 (0) | 0 (0) | 0 (0) | 3 (16) | 3 (30) | 0 (0) |
| Hostile bilateral femoral/iliac access | 11 (25) | 5 (20) | 4 (22) | 1 (14) | 6 (32) | 3 (30) | 3 (33) |
| TEVAR | 8 (57) | 3 (12) | 3 (17) | 0 (0) | 5 (26) | 2 (20) | 3 (33) |
| EVAR | 36 (43) | 22 (88) | 15 (83) | 7 (100) | 14 (74) | 8 (80) | 6 (67) |
| Days between procedures (Staged group) | 72 (IQR: 57–87) | 82 (IQR: 32–86) | 65 (IQR: 28–88) | ||||
| Intraoperative details | |||||||
| General Anaesthesia TEVAR/EVAR | 23 (52) | 14 (56) | 13 (72) | 1 (14) | 9 (47) | 3 (30) | 6 (67) |
| Percutaneous femoral access TEVAR/EVAR | 27 (61) | 16 (64) | 10 (56) | 6 (86) | 11 (58) | 4 (40) | 7 (78) |
| Percutaneous femoral access TAVI | 30 (68) | 16 (64) | 10 (56) | 6 (86) | 14 (74) | 7 (70) | 7 (78) |
| Need for iliac adjunctive procedures | 4 (9) | 1 (4) | 0 (0) | 1 (14) | 3 (16) | 2 (20) | 1 (11) |
| Technical Success | 44 (100) | 25 (100) | 18 (100) | 7 (100) | 19 (100) | 10 (100) | 9 (100) |
| Postoperative results | |||||||
| Cardiac adverse events | 2 (5) | 0 (0) | 0 (0) | 0 (0) | 2 (11) | 1 (10) | 1 (11) |
| Cerebrovascular adverse events | 2 (5) | 1 (4) | 0 (0) | 1 (14) | 1 (5) | 0 (0) | 1 (11) |
| Respiratory adverse events | 5 (11) | 0 (0) | 0 (0) | 0 (0) | 5 (26) | 2 (20) | 3 (33) |
| Reinterventions | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 1 (5) | 1 (10) | 0 (0) |
| Vascular access complication | 2 (5) | 1 (4) | 1 (6) | 0 (0) | 1 (5) | 0 (0) | 1 (11) |
| Death | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 1 (5) | 1 (10) | 0 (0) |
| . | Overall-44, N (%) . | Simultaneous group . | Staged group . | ||||
|---|---|---|---|---|---|---|---|
| . | . | Overall-25, N (%) . | EVAR first-18, N (%) . | TAVI first-7, N (%) . | Overall-19, N (%) . | EVAR first-10, N (%) . | TAVI first–9, N (%) . |
| Preoperative factors | |||||||
| Male | 30 (68) | 13 (52) | 7 (39) | 5 (71) | 17 (89) | 9 (90) | 8 (89) |
| Urgent aneurysm | 3 (7) | 0 (0) | 0 (0) | 0 (0) | 3 (16) | 3 (30) | 0 (0) |
| Hostile bilateral femoral/iliac access | 11 (25) | 5 (20) | 4 (22) | 1 (14) | 6 (32) | 3 (30) | 3 (33) |
| TEVAR | 8 (57) | 3 (12) | 3 (17) | 0 (0) | 5 (26) | 2 (20) | 3 (33) |
| EVAR | 36 (43) | 22 (88) | 15 (83) | 7 (100) | 14 (74) | 8 (80) | 6 (67) |
| Days between procedures (Staged group) | 72 (IQR: 57–87) | 82 (IQR: 32–86) | 65 (IQR: 28–88) | ||||
| Intraoperative details | |||||||
| General Anaesthesia TEVAR/EVAR | 23 (52) | 14 (56) | 13 (72) | 1 (14) | 9 (47) | 3 (30) | 6 (67) |
| Percutaneous femoral access TEVAR/EVAR | 27 (61) | 16 (64) | 10 (56) | 6 (86) | 11 (58) | 4 (40) | 7 (78) |
| Percutaneous femoral access TAVI | 30 (68) | 16 (64) | 10 (56) | 6 (86) | 14 (74) | 7 (70) | 7 (78) |
| Need for iliac adjunctive procedures | 4 (9) | 1 (4) | 0 (0) | 1 (14) | 3 (16) | 2 (20) | 1 (11) |
| Technical Success | 44 (100) | 25 (100) | 18 (100) | 7 (100) | 19 (100) | 10 (100) | 9 (100) |
| Postoperative results | |||||||
| Cardiac adverse events | 2 (5) | 0 (0) | 0 (0) | 0 (0) | 2 (11) | 1 (10) | 1 (11) |
| Cerebrovascular adverse events | 2 (5) | 1 (4) | 0 (0) | 1 (14) | 1 (5) | 0 (0) | 1 (11) |
| Respiratory adverse events | 5 (11) | 0 (0) | 0 (0) | 0 (0) | 5 (26) | 2 (20) | 3 (33) |
| Reinterventions | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 1 (5) | 1 (10) | 0 (0) |
| Vascular access complication | 2 (5) | 1 (4) | 1 (6) | 0 (0) | 1 (5) | 0 (0) | 1 (11) |
| Death | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 1 (5) | 1 (10) | 0 (0) |
EVAR: endovascular aortic repair; IQR: interquartile range; N: numbers; TAVI: transcatheter aortic valve implantation; TEVAR: thoracic endovascular aortic repair.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
